Seroprevalence of SARS-CoV-2 Antibodies and Associated Factors in Bamako, Mali: A Population-Based Cross-Sectional Study in September 2022

IF 4.3 4区医学 Q1 INFECTIOUS DISEASES

Influenza and Other Respiratory Viruses Pub Date : 2024-07-23 DOI:10.1111/irv.13343

Bourama Traoré, Merepen A. Guindo, Drissa Konaté, Fousseyni Kané, Nathan C. Incandela, Abdouramane Traore, Salimata Kanté, Mariam Sidibé, Bourama Keita, Fatoumata Kasse, Karamoko Tangara, Dramane Diallo, Issoufi Y. Maiga, Salif Thiam, Abdourhamane Cisse, Khatry M. Siby, Abdoul R. Dicko, Mariam Goita, Diakaridia Kone, Mamadou Diallo, Modibo Traore, Yaya I. Coulibaly, Mahamadou Diakité, Seydou Doumbia, Housseini Dolo, Saidou Balam

{"title":"Seroprevalence of SARS-CoV-2 Antibodies and Associated Factors in Bamako, Mali: A Population-Based Cross-Sectional Study in September 2022","authors":"Bourama Traoré, Merepen A. Guindo, Drissa Konaté, Fousseyni Kané, Nathan C. Incandela, Abdouramane Traore, Salimata Kanté, Mariam Sidibé, Bourama Keita, Fatoumata Kasse, Karamoko Tangara, Dramane Diallo, Issoufi Y. Maiga, Salif Thiam, Abdourhamane Cisse, Khatry M. Siby, Abdoul R. Dicko, Mariam Goita, Diakaridia Kone, Mamadou Diallo, Modibo Traore, Yaya I. Coulibaly, Mahamadou Diakité, Seydou Doumbia, Housseini Dolo, Saidou Balam","doi":"10.1111/irv.13343","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The sero-epidemiological characteristics of SARS-CoV-2 infections in Mali are not yet well understood. This study assessed SARS-CoV-2 antibody seroprevalence and factors associated with antibody responses in the general population of Bamako, the capital city and epicenter of COVID-19, to assess the magnitude of the pandemic and contribute to control strategy improvements in Mali.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A cross-sectional survey was conducted in September 2022 to collect sociodemographic information, clinical characteristics, comorbid factors, and blood samples. ELISA was performed to determine anti-Spike (anti-S) and anti-RBD antibody levels. A total of 3601 participants were enrolled in REDCap. R-Studio was used for the statistical analysis. The chi-squared (χ<sup>2</sup>) test was used to compare the proportions across different groups. Logistic regression models were used to elucidate factors associated with antibody responses.</p>\n </section>\n \n <section>\n \n <h3> Result</h3>\n \n <p>The sex ratio for female-to-male was 3.6:1. The most representative groups were the 20–29-year-olds (28.9%, <i>n</i> = 1043) and the 30–39-year-olds (26.9%, <i>n</i> = 967). The COVID-19 vaccine coverage among the participants was 35.8%, with vaccines from Covishield AstraZeneca (13.4%), Johnson & Johnson (16.7%), Sinovac (3.9%), and BioNTech Pfizer (1.8%). Overall, S protein and RBD antibody seroprevalences were remarkably high in the study population (98% and 97%, respectively). Factors such as youth (1–9 years old) and male sex were associated with lower SARS-CoV-2 antibody responses, whereas COVID-19 vaccinations were associated with increased antibody responses.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This serosurvey demonstrated the high seroprevalence of SARS-CoV-2 antibodies and highlighted the factors influencing antibody responses, while clearly underlining an underestimation of the pandemic in Mali.</p>\n </section>\n </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11300109/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.13343","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The sero-epidemiological characteristics of SARS-CoV-2 infections in Mali are not yet well understood. This study assessed SARS-CoV-2 antibody seroprevalence and factors associated with antibody responses in the general population of Bamako, the capital city and epicenter of COVID-19, to assess the magnitude of the pandemic and contribute to control strategy improvements in Mali.

Methods

A cross-sectional survey was conducted in September 2022 to collect sociodemographic information, clinical characteristics, comorbid factors, and blood samples. ELISA was performed to determine anti-Spike (anti-S) and anti-RBD antibody levels. A total of 3601 participants were enrolled in REDCap. R-Studio was used for the statistical analysis. The chi-squared (χ²) test was used to compare the proportions across different groups. Logistic regression models were used to elucidate factors associated with antibody responses.

Result

The sex ratio for female-to-male was 3.6:1. The most representative groups were the 20–29-year-olds (28.9%, n = 1043) and the 30–39-year-olds (26.9%, n = 967). The COVID-19 vaccine coverage among the participants was 35.8%, with vaccines from Covishield AstraZeneca (13.4%), Johnson & Johnson (16.7%), Sinovac (3.9%), and BioNTech Pfizer (1.8%). Overall, S protein and RBD antibody seroprevalences were remarkably high in the study population (98% and 97%, respectively). Factors such as youth (1–9 years old) and male sex were associated with lower SARS-CoV-2 antibody responses, whereas COVID-19 vaccinations were associated with increased antibody responses.

Conclusion

This serosurvey demonstrated the high seroprevalence of SARS-CoV-2 antibodies and highlighted the factors influencing antibody responses, while clearly underlining an underestimation of the pandemic in Mali.

Abstract Image

查看原文本刊更多论文

马里巴马科 SARS-CoV-2 抗体血清流行率及相关因素：2022 年 9 月基于人口的横断面研究。

背景：马里 SARS-CoV-2 感染的血清流行病学特征尚不十分清楚。本研究评估了马里首都巴马科（COVID-19 的震中）普通人群的 SARS-CoV-2 抗体血清流行率以及与抗体反应相关的因素，以评估疫情的严重程度，并为改进马里的控制策略做出贡献：方法：2022 年 9 月进行了一次横断面调查，收集社会人口信息、临床特征、合并因素和血液样本。采用酶联免疫吸附法测定抗斯派克（anti-S）抗体和抗 RBD 抗体水平。REDCap 共登记了 3601 名参与者。统计分析使用了 R-Studio。采用卡方（χ2）检验比较不同组别的比例。逻辑回归模型用于阐明与抗体反应相关的因素：结果：女性与男性的性别比例为 3.6:1。最具代表性的群体是 20-29 岁（28.9%，n = 1043）和 30-39 岁（26.9%，n = 967）。参与者中 COVID-19 疫苗的覆盖率为 35.8%，疫苗分别来自 Covishield AstraZeneca（13.4%）、Johnson & Johnson（16.7%）、Sinovac（3.9%）和 BioNTech Pfizer（1.8%）。总体而言，研究人群的 S 蛋白和 RBD 抗体血清阳性率非常高（分别为 98% 和 97%）。年轻（1-9 岁）和男性等因素与较低的 SARS-CoV-2 抗体反应有关，而接种 COVID-19 疫苗则与较高的抗体反应有关：这次血清调查显示了 SARS-CoV-2 抗体的高血清流行率，并强调了影响抗体反应的因素，同时清楚地凸显了对马里大流行病的低估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Influenza and Other Respiratory Viruses 医学-病毒学

CiteScore

7.20

自引率

4.50%

发文量

120

审稿时长

6-12 weeks

期刊介绍： Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases. Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.